SCHEMBL2180385

SCHEMBL2180385

CC(C)C(C(=O)O)N1Cc2cc(-c3ccc(NC(=O)c4ccc(F)cc4)cc3)ccc2C1=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.48
SDCBP O00560 4/20 0.46
SDC2 P34741 4/20 0.46
LMNA P02545 2/20 0.45
THRB P10828 1/20 0.45
TP53 P04637 2/20 0.43
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
MITF O75030 1/20 0.42
NPC1 O15118 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK14 Q16539 2/20 0.41
NAMPT P43490 2/20 0.41
DGAT1 O75907 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2182200 1.00 PTPN1 (0.48) PTPN1SDCBPSDC2LMNATHRB
SCHEMBL2180600 0.92 PTPN1 (0.48) PTPN1SDCBPSDC2LMNATHRB
SCHEMBL2180583 0.92 PTPN1 (0.48) PTPN1SDCBPSDC2LMNATHRB
SCHEMBL2178684 0.91 SDCBP (0.46) SDCBPSDC2LMNATP53MEN1
SCHEMBL2180871 0.91 SDCBP (0.46) SDCBPSDC2LMNATP53MEN1
SCHEMBL2180086 0.91 LMNA (0.49) PTPN1SDCBPSDC2LMNATHRB
SCHEMBL2180081 0.91 LMNA (0.49) PTPN1SDCBPSDC2LMNATHRB
SCHEMBL2179055 0.91 SDCBP (0.48) SDCBPSDC2LMNATHRBTP53
SCHEMBL2179062 0.91 SDCBP (0.48) SDCBPSDC2LMNATHRBTP53
SCHEMBL13719314 0.91 SDCBP (0.44) SDCBPSDC2LMNATP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT PTPN1 2065/4885SDCBP 2373/4885SDC2 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.